• Skip to primary navigation
  • Skip to content
  • Skip to footer
Gynesonics

Gynesonics

Advancing technology. Improving women's lives.

  • Our Company
    • About Us
    • Careers
    • Compliance and Quality
  • Our People
    • Management
    • Board of Directors
    • Investors
  • Our Technology
    • The Sonata System
    • Indications and Safety
    • Instructions for Use
    • Request for Medical or Scientific Information
  • Our News
    • Press Releases
    • In the News
    • Publications
  • Contact Us

Press Releases

Nov 11, 2019

Gynesonics Announces Full Launch of New Sonata 2 System at 48th AAGL Global Congress

2-year Outcomes Data from the SONATA IDE Pivotal Trial To Be Presented, Demonstrating Significant and Sustained Symptom Relief REDWOOD CITY, Calif. – November 11, 2019 – Gynesonics, a women’s healthcare company focused on the development of minimally-invasive solutions for symptomatic uterine fibroids, announced today the full launch of the Sonata® 2 System in the United […]

Nov 8, 2019

Gynesonics Names Kelly U. Petrucci Vice President of Healthcare Economics and Market Access

Joins Experienced Team to Accelerate Global Launch of the new Sonata 2 System Redwood City, CA – November 8, 2019 – Gynesonics, a women’s healthcare company focused on the development of minimally-invasive solutions for symptomatic uterine fibroids, announced today that medical device executive Kelly U. Petrucci has been named Vice President of Healthcare Economics and […]

Mar 5, 2019

Gynesonics Announces Five-Year Patient Outcomes with the Sonata System Published in Journal of Gynecologic Surgery

VITALITY Study Demonstrates the Long-Term Durability of Patient Outcomes  In Treating Symptomatic Uterine Fibroids Redwood City, CA – March 5, 2019 – Gynesonics, a women’s healthcare company and the developer of the Sonata® system for the treatment of uterine fibroids (also known as leiomyomas) today announced the publication of the VITALITY study in the Journal […]

Jan 10, 2019

Gynesonics Announces Publication of Final SONATA IDE Pivotal Trial Results in the Journal, Obstetrics And Gynecology

Robust Outcomes Support the Potential of the Sonata System as a  First-Line Treatment for Symptomatic Uterine Fibroids Redwood City, CA – January 10, 2019 – Gynesonics, a women’s healthcare company and the developer of the Sonata® system for the treatment of uterine fibroids (also known as leiomyomas) today announced the publication of the SONATA IDE […]

Jan 3, 2019

Gynesonics Announces $75 Million Equity Financing

Equity Round led by Bain Capital Life Sciences Redwood City, CA – January 3, 2019 – Gynesonics, a women’s healthcare company and the developer of the Sonata System and other advanced, incision-free solutions for the treatment of uterine conditions, today announced that it has completed a $75 million equity financing. The financing was led by […]

Nov 12, 2018

Gynesonics Technology to be Featured in Presentations at 2018 AAGL Global Congress

Impressive 12-Month Patient Outcomes from SONATA Pivotal IDE Trial Being Highlighted Redwood City, CA – Nov 12, 2018 – Gynesonics, a women’s healthcare company focused on the development of advanced minimally invasive solutions for the treatment of uterine conditions, today announced that its Sonata® System for transcervical treatment of uterine fibroids will be featured in […]

Aug 22, 2018

Gynesonics Receives FDA Clearance to Market Sonata® System

Advanced technology offers potential to become a new standard of care for fibroid treatment Redwood City, CA – August 22, 2018 – Gynesonics, a women’s healthcare company focused on the development of minimally-invasive solutions for symptomatic uterine fibroids, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to […]

Jan 9, 2018

Gynesonics Announces Results from Pivotal IDE Trial for Incision Free Treatment of Uterine Fibroids

Results highlight robust Sonata System design and its potential to become a standard of care for fibroid treatment Redwood City, CA – January 9, 2018 – Gynesonics, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, today announced the results from their pivotal IDE trial for the Sonata® […]

Dec 21, 2017

Gynesonics Announces Submission of FDA 510K for Incision-Free Treatment of Symptomatic Uterine Fibroids

Novel uterus-preserving Sonata System is first incision-free treatment to address majority of fibroids transcervically Redwood City, CA – December 21, 2017 – Gynesonics, a women’s healthcare company focused on the development of minimally invasive solutions for uterine fibroids, today announced its submission to the FDA of its 510(k) Premarket Notification for the Sonata® System, a […]

Mar 30, 2017

Gynesonics names James Sparks Vice President of Manufacturing

Respected Leader in Medical Device Manufacturing and Engineering Management Redwood City, CA – March 30, 2017 – Gynesonics, a women’s healthcare company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of symptomatic uterine fibroids, today announced that medical device executive James Sparks has been named Vice President […]

  • « Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • Next »

Footer

  • Privacy Notice
  • Cookie Notice
  • Do Not Sell/Share My Personal Information
  • Limit the Use of My Sensitive Personal Information
  • Terms of Use
  • Impressum
  • Patents
  • Safety Information

© Copyright 2023 Gynesonics · All Rights Reserved · WS 05198 Rev. L